- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05135559
Un estudio de investigación sobre qué tan bien funciona el concizumab para usted si tiene hemofilia A o B con o sin inhibidores (Explorer10)
Estudio abierto que investiga la eficacia, la seguridad y la farmacocinética de la profilaxis con concizumab en niños menores de 12 años con hemofilia A o B con o sin inhibidores
This study will test how well a new medicine called concizumab works for participants who have haemophilia A or B with or without inhibitors. The purpose is to show that concizumab can prevent bleeds and is safe to use.
Participants will have to inject the study medicine every day under the skin with a pen-injector.
The study will last for at least 2 years and up to about 4 years. The length of time the participant will be in the study depends on if the study medicine will be available for purchase in their country.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Acceso ampliado
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Algiers, Argelia, 16000
- Haematology and Blood Bank Department
-
Constantine, Argelia, 25000
- CHU Constantine BEN BADIS/ Hematology department
-
-
-
-
-
Banja Luka, Bosnia y Herzegovina, 78000
- University Clinical Center of Republic Srpska (545)
-
Tuzla, Bosnia y Herzegovina, 75000
- University Clinical Centre Tuzla
-
-
-
-
-
Plovdiv, Bulgaria, 4002
- UMHAT Sveti Georgi EAD, Plovdiv, Clinic of Pediatrics
-
Sofia, Bulgaria, 1527
- UMHAT Tsaritsa Yoanna - ISUL EAD, Pediatric clinical hematology and oncology
-
Varna, Bulgaria, 9010
- UMHAT Sveta Marina EAD, Clinic of Pediatric Clinical Hematology and Oncology
-
-
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6H 3V4
- BC Children's Hospital
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8N 3Z5
- McMaster Children's Hospital
-
-
-
-
-
Barcelona, España, 08035
- Hospital Vall d'Hebron
-
Madrid, España, 28046
- Hospital Universitario La Paz
-
Málaga, España, 29009
- Hospital Regional Universitario de Málaga
-
-
Murcia
-
El Palmar, Murcia, España, 30120
- Hospital Virgen de la Arrixaca - Hematología
-
-
-
-
California
-
San Diego, California, Estados Unidos, 92123
- Rady Childrens Hosp San Diego
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- University of Colorado Hospital
-
-
Florida
-
Orlando, Florida, Estados Unidos, 32806
- Arnold Palmer Children's Hospital
-
Orlando, Florida, Estados Unidos, 32827
- Nemours Child Orlando Hem/Onc.
-
-
Georgia
-
Augusta, Georgia, Estados Unidos, 30912
- Augusta Univ/Childrens Hosp-GA
-
Savannah, Georgia, Estados Unidos, 31404
- Memorial Health University Medical Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Childrens Hospital of Chicago
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46260
- Indiana Hemophilia-Thromb Ctr
-
-
Louisiana
-
New Orleans, Louisiana, Estados Unidos, 70121
- Ochsner Clinic Foundation
-
New Orleans, Louisiana, Estados Unidos, 70118
- Children's Hosp-New Orleans
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64108
- The Children's Mercy Hospital
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68114
- Children's Nebraska
-
-
North Carolina
-
Greenville, North Carolina, Estados Unidos, 27834
- ECU Sickle Cell Comp Clinic
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19134
- St Christopher Hosp for Child
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Monroe Carell Jr. Children's Hospital at Vanderbilt
-
-
Texas
-
Fort Worth, Texas, Estados Unidos, 76104
- Cook Children's Hospital-Hematology-Oncology
-
Houston, Texas, Estados Unidos, 77030
- Texas Children's Hospital_Houston
-
-
Virginia
-
Charlottesville, Virginia, Estados Unidos, 22908
- Pediatrics Hematology/Oncology Clinic Battle Building
-
-
-
-
-
Tallinn, Estonia, 13419
- Tallinn Children's Hospital
-
-
-
-
-
Chambéry, Francia, 73000
- Centre Hospitalier Metropole Savoie
-
Le Kremlin-Bicêtre, Francia, 94275
- Ap-Hp-Hopital de Bicetre-1
-
Paris, Francia, 75015
- AP-HP-HOPITAL NECKER_Service d'hématologie
-
-
-
-
-
Athens, Grecia, GR-11527
- Aghia Sophia Childrens' Hospital
-
Thessaloniki, Grecia, GR 54642
- 'Ippokrateio' General Hospital of Thessaloniki
-
Thessaloniki, Grecia, 54642
- 'Ippokrateio' General Hospital of Thessaloniki
-
-
-
-
Assam
-
Guwahati, Assam, India, 781032
- Guwahati Medical College
-
-
Gujarat
-
Surat, Gujarat, India, 395002
- Nirmal Hospital Pvt. Ltd.
-
-
Maharashtra
-
Kolhāpur, Maharashtra, India, 416005
- SSSH_Dept. of Clinical Haematology & Haemato Oncology
-
Mumbai, Maharashtra, India, 400012
- Seth GS Medical College & KEM Hospital
-
Mumbai, Maharashtra, India, 400022
- K.J Somaiya Hospital and Research Centre
-
Mumbai, Maharashtra, India, 400066
- MCGM - Comprehensive Thalassemia Care
-
Pune, Maharashtra, India, 411004
- Sahyadri Super Speciality Hospital
-
-
Odisha
-
Cuttack, Odisha, India, 753007
- S.C.B. Medical College
-
-
Rajasthan
-
Jaipur, Rajasthan, India, 302004
- J K Lon Hospital
-
-
Uttar Pradesh
-
Noida, Uttar Pradesh, India, 201303
- Post Graduate Institute of Child Health
-
-
Uttart Pradesh
-
Lucknow, Uttart Pradesh, India, 226014
- SGPGI
-
-
-
-
-
Catania, Italia, 95123
- A.O.U policlinico "G. Rodolico-San Marco"
-
Florence, Italia, 50134
- Dipartimento di Ematologia Univ. Firenze
-
Padova, Italia, 35128
- Azienda Ospedaliera di Padova _
-
Parma, Italia, 43126
- Azienda Ospedaliera-Universitaria Parma
-
-
-
-
-
Kanagawa, Japón, 216-8511
- St. Marianna University School of Medicine Hospital_Pediatrics
-
Saitama, Japón, 330-8777
- Saitama Children's Med Centre_Hematology-Oncology
-
-
-
-
-
Vilnius, Lituania, LT-08406
- Centre of Oncology and Hematology, Vilnius University
-
-
-
-
-
Beirut, Líbano, 961
- Saint George Hospital University Medical Center
-
Tripoli, Líbano, 1434
- Hospital Nini
-
-
-
-
-
Skopje, Macedonia del norte, 1000
- PHI University Clinic for Children's Diseases Skopje
-
-
-
-
Kuala Lumpur
-
Kampung Baru, Kuala Lumpur, Malasia, 50300
- Hospital Tunku Azizah
-
-
Pulau Pinang
-
George Town, Pulau Pinang, Malasia, 10450
- Hospital Pulau Pinang
-
-
Sarawak
-
Kuching, Sarawak, Malasia, 93586
- Sarawak General Hospital
-
-
Terengganu
-
Kuala Terengganu, Terengganu, Malasia, 20400
- Hospital Sultanah Nur Zahirah
-
-
-
-
-
Oslo, Noruega, 0372
- Klinisk forskningspost
-
-
-
-
-
Gdansk, Polonia, 80-952
- Uniwersyteckie Centrum Kliniczne
-
Lublin, Polonia, 20-093
- Uniwersytecki Szpital Dzieciecy, Dzial Krwiolecznictwa
-
Warsaw, Polonia, 02-091
- Uniwersyteckie Centrum Kliniczne WUM
-
-
Lower Silesian Voivodeship
-
Wroclaw, Lower Silesian Voivodeship, Polonia, 50-556
- Uniwersytecki Szpital Kliniczny im. J.Mikulicza-Radeckiego
-
-
-
-
-
Birmingham, Reino Unido, B4 6NH
- Birmingham Children's Hospital
-
Bristol, Reino Unido, BS2 8BJ
- University Hospitals Bristol & Weston NHS Foundation Trust
-
London, Reino Unido, WC1N 3HR
- Great Ormond Street Hospital for Children
-
London, Reino Unido, SE1 7EH
- Evelina London Children's Hospital - Haemophilia
-
-
-
-
-
Bucharest, Rumania, 022328
- Clinic of Haematology, Fundeni Clinical Institute
-
Cluj-Napoca, Rumania, 400177
- Spitalul Clinic de Urgenta pentru Copii Cluj Napoca
-
Oradea, Rumania, 410469
- Spitalul Clinic Judetean De Urgenta Bihor
-
-
-
-
Gauteng
-
Parktown, Johannesburg, Gauteng, Sudáfrica, 2193
- Charlotte Maxeke Johannesburg Academic Hospital
-
-
-
-
-
Gothenburg, Suecia, 413 46
- Sahlgrenska US - Koagulationscentrum
-
-
-
-
-
Bangkok, Tailandia, 10400
- Ramathibodi Hospital
-
Bangkok, Tailandia, 10330
- King Chulalongkorn Memorial Hospital_Bangkok_0
-
Bangkok, Tailandia, 10700
- Siriraj Hospital - Hematology and Oncology
-
Bangkok, Tailandia, 10330
- King Chulalongkorn Memorial Hospital_Pediatric Hematology-Oncology
-
-
Mueang Distirct,
-
Ubon Ratchathani, Mueang Distirct,, Tailandia, 34000
- Sunpasitthiprasong Hospital_Pediatrics Department
-
-
-
-
-
Adana, Turquía (Türkiye), 01130
- Acibadem Adana Hastanesi
-
Adana, Turquía (Türkiye), 01130
- Acıbadem Adana Hastanesi-Hematoloji
-
Izmir, Turquía (Türkiye), 35100
- Ege Universitesi Tip Fakultesi
-
Izmir, Turquía (Türkiye), 35100
- Ege Üniversitesi Hastanesi- Hematoloji
-
Samsun, Turquía (Türkiye), 55139
- Ondokuz Mayis University Medical Faculty Ped. Haematology
-
Samsun, Turquía (Türkiye), 55139
- Ondokuz Mayıs Üniversitesi Hastanesi - Hematoloji
-
-
Beşevler/Ankara
-
Ankara, Beşevler/Ankara, Turquía (Türkiye), 06500
- Gazi University
-
Ankara, Beşevler/Ankara, Turquía (Türkiye), 06500
- Gazi Üniversitesi Hastanesi- Hematoloji
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
- Adulto Mayor
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Informed consent/assent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
-
Diagnosis of congenital severe haemophilia A (FVIII below 1%) or moderate/severe congenital haemophilia B (FIX (coagulation factor IX) below or equal to 2%), or congenital haemophilia with inhibitors.
-
For arm 1 only: Male aged below 12 years of age at the time of signing informed consent.
-
For arm 1 only: Patients with inhibitors (haemophilia A with inhibitors or haemophilia B with inhibitors)
- Patients with HAwI (haemophilia A with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
- Patients with HBwI (haemophilia B with inhibitors) with historical medical records of a total of at least 26 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available).
- Patients with HBwI regardless of the regimen and duration of previous haemophilia treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products)
-
For arm 1 only: Patients without inhibitors (haemophilia A or haemophilia B)
- Patients with historical medical records of at least 52 weeks of on-demand treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products; Surgery related PPX or short-term PPX (e.g., in relation to a severe bleed) is not allowed) during the last year prior to enrolment and with at least 3 documented treated bleeds (For participants less than (<) 2 years of age there is no limitation for number of documented treated bleeds in the medical history) during this period
- Patients with historical medical records of a total of at least 26 weeks of PPX (prophylaxis) treatment (On-demand or PPX treatment qualifying for this study is understood as patient-treatment solely for bleeds with intravenous coagulation factor-containing products) within the last 52 weeks prior to enrolment (For patients below 1 year of age that have been diagnosed with haemophilia <1 year prior to enrolment, historical medical records from time of diagnosis will suffice as long as medical records of a total of at least 26 weeks of relevant treatment is available)
-
For arm 2 only: Male patients (regardless of age) previously treated with concizumab via compassionate use.
Exclusion Criteria:
- Known or suspected hypersensitivity to study intervention or related products.
- Known inherited or acquired coagulation disorder other than congenital haemophilia.
- Ongoing or planned Immune Tolerance Induction treatment.
- History of thromboembolic disease (aIncludes arterial and venous thrombosis including myocardial infarction, pulmonary embolism, cerebral infarction/thrombosis, deep vein thrombosis, other clinically significant thromboembolic events and peripheral artery occlusion.). Current clinical signs of or treatment for thromboembolic disease. Patients who in the judgement of the investigator are considered at high risk of thromboembolic events (Thromboembolic risk factors could include, but are not limited to, hypercholesterolemia, diabetes mellitus, hypertension, obesity, smoking, family history of thromboembolic events, arteriosclerosis, other conditions associated with increased risk of thromboembolic events).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Concizumab-naïve patients
Concizumab-naïve participants below 12 years of age at the time of consent/assent |
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose. |
|
Experimental: Patients coming from compassionate use
Patients previously treated with concizumab via compassionate use, either on an individual patient basis or through the concizumab compassionate use programme NN7415-4807 |
Participants in Arm 1 will be assigned to concizumab prophylaxis starting with a loading dose on treatment day 0 followed by daily injections of an individual maintenance dose. Participants in Arm 2 will be assigned to concizumab prophylaxis with daily injections of an individual maintenance dose. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For inhibitor patients with at least 26 weeks on-demand treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand during at least the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients treated on-demand at least the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous and traumatic bleeding episodes
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of all bleeding episodes (spontaneous and traumatic)
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated spontaneous bleeding episodes
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated joint bleeding episodes
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
For non-inhibitor patients with at least 26 weeks PPX treatment during the last 52 weeks prior enrolment: Number of treated bleeding episodes in baseline target joints
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of episode(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Concizumab-naïve pateints - Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of thromboembolic events, reported both separately for inhibitor and non-inhibitor patients and combined
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of hypersensitivity type reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of injection site reactions, reported both separately for inhibitor and non-inhibitor patients and combined
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of patients who develop antibodies to concizumab - yes/no, reported both separately for inhibitor and non-inhibitor patients and combined
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of patient(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Number of treatment emergent adverse events, reported both separately for inhibitor and non-inhibitor patients and combined
Periodo de tiempo: From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
Count of event(s) |
From start of treatment (week 0) up until the primary analysis cut-off (at least 32 weeks)
|
|
Concizumab plasma concentrations prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Periodo de tiempo: Week 32
|
Measured in ng/mL |
Week 32
|
|
Peak thrombin generation prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Periodo de tiempo: Week 32
|
Measured in nM |
Week 32
|
|
Free TFPI concentration prior to dosing, reported both separately for inhibitor and non-inhibitor patients and combined
Periodo de tiempo: Week 32
|
Measured in ng/mL |
Week 32
|
|
Pre-dose (trough) concizumab plasma concentration (Ctrough), reported both separately for inhibitor and non-inhibitor patients and combined
Periodo de tiempo: Prior to the concizumab administration at week 20
|
Measured in ng/mL |
Prior to the concizumab administration at week 20
|
|
Maximum concizumab plasma concentration (Cmax), reported both separately for inhibitor and non-inhibitor patients and combined
Periodo de tiempo: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Measured in ng/mL |
From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
|
Area under the concizumab plasma concentration-time curve (AUC), reported both separately for inhibitor and non-inhibitor patients and combined
Periodo de tiempo: From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Measured in ng*hr/mL |
From 0 to 24 hours where 0 is the time of the concizumab dose at week 20
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades Genéticas Congénitas
- Enfermedades hematológicas
- Trastornos de la coagulación de la sangre
- Trastornos hemorrágicos
- Trastornos de la coagulación de la sangre, hereditarios
- Trastornos de proteínas de coagulación
- Enfermedades y anomalías congénitas, hereditarias y neonatales
- Enfermedades hemic y linfáticas
- Hemofilia A
- concizumab
Otros números de identificación del estudio
- NN7415-4616
- U1111-1247-7330 (Otro identificador: World Health Organization (WHO))
- 2020-000504-11 (Número EudraCT)
- jRCT2031220097 (Identificador de registro: JAPIC)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .